A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH

• Status: Completed
• Trial end date: 2019-10-22
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase IIa, open-label, multiple dose, study in patients with PNH who have not received eculizumab (Soliris ®) in the past. A single cohort of subjects is planned for evaluation.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Apellis Pharmaceuticals, Inc.

Criteria

Inclusion Criteria:

• At least 18 years old (inclusive)

• Diagnosed with PNH (white blood cell (WBC) clone >10%)

• Lactose dehydrogenase (LD) ≥2 times the upper limit of normal

• Screening Ferritin ≥ normal and Total Iron Binding Capacity (TIBC) < LLN based on central lab reference ranges. If a subject is receiving iron supplements at screening, the investigator must ensure that his/her dose has been stable for 8 weeks prior to enrolment and must be maintained throughout the study

• Last transfusion within 12 months prior to screening

• Platelet count of >30,000/mm3 at the screening visit

• Absolute neutrophil count >500/ mm3 at the screening visit

• Women of child-bearing potential (WOCBP) must have a negative pregnancy test at screening and must agree to use protocol defined methods of contraception for the duration of the study

• Males must agree to use protocol defined methods of contraception and agree to refrain from donating sperm for the duration of the study

• Vaccination against Neisseria meningitides types A, C, W, Y and B, Streptococcus pneumoniae and Haemophilus influenzae Type B (Hib) either within 2 years prior to Day 1 dosing, or within 14 days after starting treatment with pegcetacoplan. Unless documented evidence exists that subjects are non-responders to vaccination as evidenced by titers or display titer levels within acceptable local limits

• Willing and able to give informed consent

Exclusion Criteria:

• Prior eculizumab (Soliris®) treatment

• Active bacterial infection

• Hereditary complement deficiency

• History of bone marrow transplantation

• Concurrent severe aplastic anemia (SAA), defined as currently receiving immunosuppressive therapy for SAA including but not limited to cyclosporin A, tacrolimus, mycophenolate mofetil or anti-thymocyte globulin

• Participation in any other investigational drug trial or exposure to another investigational agent, device or procedure within 30 days

• Evidence of QTcF prolongation defined as >450 ms for males and >470 ms for females at screening

• Breast-feeding women

• History of meningococcal disease